{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:45:23Z","timestamp":1790390723259,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.beem.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,6,19]],"date-time":"2016-06-19T00:10:52Z","timestamp":1466295052000},"page":"397-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Optimizing management of glycaemia"],"prefix":"10.1016","volume":"30","author":[{"given":"Sudesna","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2016.06.002_bib1","series-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib2","series-title":"Diabetes prevalence 2014","author":"Diabetes UK","year":"2015"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib3","first-page":"1","article-title":"Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors","volume":"13","author":"UK Prospective Diabetes Study 6","year":"1990","journal-title":"Diabetes Res"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/dom.12569","article-title":"Factors associated with failure to achieve hemoglobin A1c < 8.0% in the action to control cardiovascular risk in diabetes trial","volume":"18","author":"Drake","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.beem.2016.06.002_bib6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11892-013-0371-2","article-title":"Hyperglycemia and vascular metabolic memory: truth or fiction?","volume":"13","author":"Bianchi","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"9","key":"10.1016\/j.beem.2016.06.002_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9131","key":"10.1016\/j.beem.2016.06.002_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beem.2016.06.002_bib10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.beem.2016.06.002_bib11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2016.06.002_bib13","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"issue":"9677","key":"10.1016\/j.beem.2016.06.002_bib14","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"issue":"9153","key":"10.1016\/j.beem.2016.06.002_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.beem.2016.06.002_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beem.2016.06.002_bib17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.beem.2016.06.002_bib18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.beem.2016.06.002_bib19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.beem.2016.06.002_bib20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9982","key":"10.1016\/j.beem.2016.06.002_bib21","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.06.002_bib23","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2016.06.002_bib24","series-title":"Researching cardiovascular events with a weekly incretin in diabetes (REWIND)","author":"Eli Lilly","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib25","series-title":"Trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN 6)","author":"Novo Nordisk","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib26","series-title":"Effect of albiglutide, when added to standard blood glucose-lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus","author":"GlaxoSmithKline","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","author":"Zinman","year":"20153732117","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.06.002_bib28","series-title":"Janssen research and development LLC","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib29","series-title":"Multicenter trial to investigate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58)","author":"Astra Zeneca","year":"2015"},{"key":"10.1016\/j.beem.2016.06.002_bib30","series-title":"Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial","author":"Novo Nordisk","year":"2016"},{"key":"10.1016\/j.beem.2016.06.002_bib31","series-title":"Victoza\u00ae significantly reduces the risk of major adverse cardiovascular events in the LEADER trial","author":"Novo Nordisk","year":"2016"},{"issue":"10","key":"10.1016\/j.beem.2016.06.002_bib32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1464-5491.2005.01644.x","article-title":"Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study","volume":"22","author":"Peyrot","year":"2005","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/dme.12245","article-title":"Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes","volume":"30","author":"Nicolucci","year":"2013","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/dme.12242","article-title":"Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national comparisons on barriers and resources for optimal care\u2013healthcare professional perspective","volume":"30","author":"Holt","year":"2013","journal-title":"Diabet Med"},{"issue":"15","key":"10.1016\/j.beem.2016.06.002_bib35","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.288.15.1909","article-title":"Improving primary care for patients with chronic illness: the chronic care model, part 2","volume":"288","author":"Bodenheimer","year":"2002","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2016.06.002_bib36","series-title":"NICE. Type 2 diabetes: the management of type 2 diabetes","first-page":"CG87","year":"2009"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2016.06.002_bib37","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc08-S097","article-title":"National standards for diabetes self-management education","volume":"31","author":"Funnell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.06.002_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-12-213","article-title":"Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis","volume":"12","author":"Steinsbekk","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"AHEAD Research Group","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.beem.2016.06.002_bib40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.beem.2016.06.002_bib42","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-156-12-201206190-02012","article-title":"Meta-analysis: self-monitoring in non-insulin-treated type 2 diabetes improved HbA1c by 0.25%","volume":"156","author":"Willett","year":"2012","journal-title":"Ann Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2016.06.002_bib43","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.2337\/dc15-S009","article-title":"Glycemic targets","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","article-title":"Potential overtreatment of diabetes mellitus in older adults with tight glycemic control","volume":"175","author":"Lipska","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2016.06.002_bib46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc14-0599","article-title":"Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia","volume":"38","author":"Thorpe","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.06.002_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.diabres.2012.11.016","article-title":"Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care","volume":"99","author":"Peyrot","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.beem.2016.06.002_bib49","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.beem.2016.06.002_bib50","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/diacare.28.10.2543","article-title":"Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem","volume":"28","author":"Polonsky","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.06.002_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.curtheres.2013.06.004","article-title":"Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)","volume":"75","author":"Grandy","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib52","first-page":"682","article-title":"Bariatric surgery versus intensive medical therapy for diabetes","volume":"371","author":"Schauer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2016.06.002_bib53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1464-5491.2003.00937.x","article-title":"Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year","volume":"20","author":"Dhindsa","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.beem.2016.06.002_bib54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/pgmj.2008.068197","article-title":"Hypoglycaemia: current management and controversies","volume":"87","author":"Choudhary","year":"2011","journal-title":"Postgrad Med J"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study","volume":"38","author":"Khunti","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.beem.2016.06.002_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2337\/dc15-0279","article-title":"Minimizing hypoglycemia in diabetes","volume":"38","author":"International Hypoglycaemia Study Group","year":"2015","journal-title":"Diabetes Care"},{"issue":"9855","key":"10.1016\/j.beem.2016.06.002_bib57","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(12)61422-6","article-title":"Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial","volume":"380","author":"Simmons","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/dme.12410","article-title":"Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial","volume":"31","author":"Black","year":"2014","journal-title":"Diabet Med"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2016.06.002_bib59","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.2337\/dc11-s216","article-title":"The pros and cons of diagnosing diabetes with A1C","volume":"34","author":"Bonora","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"J\u00a0Am Med Assoc"},{"issue":"7642","key":"10.1016\/j.beem.2016.06.002_bib61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/bmj.39474.922025.BE","article-title":"Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial","volume":"336","author":"Davies","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2016.06.002_bib62","doi-asserted-by":"crossref","first-page":"e2333","DOI":"10.1136\/bmj.e2333","article-title":"Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care","volume":"344","author":"Khunti","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib63","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib64","first-page":"336","article-title":"Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes","volume":"17","author":"Mannucci","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"10.1016\/j.beem.2016.06.002_bib65","first-page":"854","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"35","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.beem.2016.06.002_bib68","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00125-012-2653-7","article-title":"Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials","volume":"55","author":"Stevens","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2016.06.002_bib69","series-title":"A\u00a0comparative effectiveness study of major glycemia-lowering medications for treatment of type 2 diabetes (GRADE)","author":"GRADE Study Group","year":"2015"},{"issue":"8","key":"10.1016\/j.beem.2016.06.002_bib70","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2337\/db14-0609","article-title":"Metformin pharmacogenomics: biomarkers to mechanisms","volume":"63","author":"Wang","year":"2014","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.beem.2016.06.002_bib71","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1479164115570301","article-title":"Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA(R))","volume":"12","author":"Marx","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"12","key":"10.1016\/j.beem.2016.06.002_bib73","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.2337\/dc12-0954","article-title":"The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes","volume":"35","author":"Vaccaro","year":"2012","journal-title":"Diabetes Care"},{"issue":"9493","key":"10.1016\/j.beem.2016.06.002_bib74","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.beem.2016.06.002_bib75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1463-1326.2011.01404.x","article-title":"High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive","volume":"13","author":"Ferrannini","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther"},{"issue":"9683","key":"10.1016\/j.beem.2016.06.002_bib77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib78","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2337\/dc12-2504","article-title":"A\u00a0critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib79","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A\u00a0critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.beem.2016.06.002_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"J\u00a0Am Med Assoc"},{"issue":"11","key":"10.1016\/j.beem.2016.06.002_bib81","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"10.1016\/j.beem.2016.06.002_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2016.06.002_bib83","first-page":"1","article-title":"Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents","volume":"0","author":"Gnudi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.beem.2016.06.002_bib84","series-title":"FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain","author":"US Food and Drug Administration","year":"2015"},{"issue":"10","key":"10.1016\/j.beem.2016.06.002_bib85","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","article-title":"The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors","volume":"63","author":"Wilding","year":"2014","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2016.06.002_bib87","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.beem.2016.06.002_bib88","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12325-013-0039-y","article-title":"Complementing insulin therapy to achieve glycemic control","volume":"30","author":"Barnett","year":"2013","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsboll","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.beem.2016.06.002_bib91","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib92","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.beem.2016.06.002_bib93","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.beem.2016.06.002_bib94","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.beem.2016.06.002_bib95","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.beem.2016.06.002_bib96","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/dc14-0649","article-title":"Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes","volume":"38","author":"Porcellati","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.beem.2016.06.002_bib97","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"Yki-Jarvinen","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.beem.2016.06.002_bib98","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"issue":"9825","key":"10.1016\/j.beem.2016.06.002_bib99","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2016.06.002_bib100","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2337\/diacare.28.5.1240","article-title":"The use of U-500 in patients with extreme insulin resistance","volume":"28","author":"Cochran","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.beem.2016.06.002_bib101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/dia.2012.0105","article-title":"The emergence of biosimilar insulin preparations\u2013a cause for concern?","volume":"14","author":"Owens","year":"2012","journal-title":"Diabetes Technol Ther"},{"issue":"18","key":"10.1016\/j.beem.2016.06.002_bib102","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2016.06.002_bib103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2016.06.002_bib104","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12498","article-title":"One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial","author":"Gough","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2016.06.002_bib105","series-title":"Sanofi (SNY)'s lixilan hits phase III goal","author":"Sanofi-Aventis","year":"2015"},{"issue":"9626","key":"10.1016\/j.beem.2016.06.002_bib106","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beem.2016.06.002_bib107","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2016.06.002_bib108","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X16300197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X16300197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:51:04Z","timestamp":1761497464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X16300197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1521690X16300197"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2016.06.002","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing management of glycaemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}